Stock Traders Buy Large Volume of Call Options on GoodRx (NASDAQ:GDRX)

Key Points

• GoodRx Holdings, Inc. experienced a significant surge in options trading, with traders purchasing 11,377 call options, marking an increase of approximately 1,680% compared to its average volume.
• Major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock at an average price of $4.80, totaling over $51,000.
• The stock's performance saw it trading at $5.12 on Monday, with a market cap of $1.78 billion and institutional investors holding 63.77% of the company's shares.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) saw unusually large options trading activity on Monday. Traders bought 11,377 call options on the company. Thisisanincreaseofapproximately1,680% compared to the average volume of 639 call options.

Insider Activity at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.17% of the company's stock.

Institutional Trading of GoodRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in GDRX. Citizens Financial Group Inc. RI purchased a new position in shares of GoodRx in the first quarter valued at $44,000. Jump Financial LLC purchased a new position in shares of GoodRx in the first quarter valued at $49,000. Cetera Investment Advisers purchased a new position in shares of GoodRx in the second quarter valued at $50,000. Walled Lake Planning & Wealth Management LLC purchased a new position in shares of GoodRx in the second quarter valued at $55,000. Finally, Deerfield Management Company L.P. Series C purchased a new position in shares of GoodRx in the fourth quarter valued at $56,000. Institutional investors own 63.77% of the company's stock.

GoodRx Stock Performance

NASDAQ:GDRX traded up $1.39 during mid-day trading on Monday, hitting $5.12. 54,723,824 shares of the company traded hands, compared to its average volume of 1,836,597. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. The stock's fifty day moving average price is $4.56 and its 200-day moving average price is $4.51. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of 51.20, a price-to-earnings-growth ratio of 1.53 and a beta of 1.24. GoodRx has a one year low of $3.31 and a one year high of $8.80.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%. The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same period last year, the business earned $0.08 EPS. The firm's quarterly revenue was up 1.2% compared to the same quarter last year. Research analysts anticipate that GoodRx will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Raymond James Financial lowered GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Wells Fargo & Company cut their target price on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. The Goldman Sachs Group lowered their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Finally, UBS Group reduced their target price on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $5.80.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.